Undifferentiated (embryonal) sarcoma

Summary

Undifferentiated (embryonal) sarcoma (MONDO:0005102) is a cancer and 5 clinical trials. Top therapeutic interventions include lurbinectedin and nivolumab. A subtype of liver sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	undifferentiated (embryonal) sarcoma
Mondo ID	MONDO:0005102
EFO	EFO:0000730
NCIT	C27096
UMLS	C0855073
MedGen	163512
GARD	0008650
Is cancer (heuristic)	yes

Also known as: embryonal sarcoma · embryonal sarcoma (undifferentiated sarcoma) · embryonal sarcoma, undifferentiated · sarcoma, undifferentiated, malignant · UES · undifferentiated (embryonal) sarcoma · undifferentiated sarcoma

Disease family

This is a subtype of liver sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › liver cancer › liver sarcoma › undifferentiated (embryonal) sarcoma

Related subtypes (6): liver angiosarcoma, liver rhabdomyosarcoma, bile duct sarcoma, liver leiomyosarcoma, liver extraskeletal osteosarcoma, liver fibrosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05918640	PHASE1/PHASE2	RECRUITING	Lurbinectedin in FET-Fused Tumors
NCT03241745	PHASE2	COMPLETED	A Study of Nivolumab in Selected Uterine Cancer Patients
NCT03651375	PHASE2	UNKNOWN	Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
NCT04995003	PHASE1	RECRUITING	HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
NCT03009201	PHASE1	COMPLETED	Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LURBINECTEDIN	4	1
NIVOLUMAB	4	1
CHEMBL5397028	0	1